Key result
Very ultra low dose aspirin significantly reduces bleeding time and prolongs thrombin clotting time.
Why the study?
The effects of aspirin at very ultra low dosage on bleeding time, platelet aggregation, and coagulation in healthy volunteers were not well characterized.
Does very ultra low dosage aspirin affect bleeding time, platelet aggregation, and coagulation in healthy volunteers?
RCT (n=20)
double-blind
randomized
Does very ultra low dosage aspirin affect bleeding time, platelet aggregation, and coagulation in healthy volunteers?
p-value: p=<0.05
Very ultra low dosage aspirin alters bleeding time and thrombin clotting time in healthy volunteers without significantly affecting platelet aggregation.
Ultra-low-dose aspirin may shorten bleeding time after prior exposure without altering aggregation; extends dose-response insights but leaves clinical adoption open pending patient trials.
Aspirin at very ultra low dosage was tested in healthy volunteers (n = 20) in a randomized, double-blind and placebo-controlled trial. The results showed a bleeding time reduction (p less than 0.05) in volunteers having previously ingested aspirin. Platelet aggregation on platelet-rich plasma was not statistically modified after aspirin ingestion. Thrombin clotting time was always higher (p less than 0.05) in the treated group.
No takes yet. Share an insight, caveat, or question.
Doutremépuich et al. (2009) conducted an RCT in Healthy volunteers (n=20). Aspirin vs. placebo was evaluated on Bleeding time (p=<0.05). Aspirin at very ultra low dosage reduced bleeding time (p<0.05) and increased thrombin clotting time (p<0.05) in healthy volunteers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: